Roger S. Newton is Director at Esperion Therapeutics, Inc. (ESPR). They have made 8 open-market trades across 1 company since 2013, most recently 2019-03-12.
CIK 0001242612
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $593K since 2013, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ESPR | 548,726 | $1.8M |
Shares reported on the most recent Form 4, priced at the 2019-03-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ESPR | SELL | 2019-03-12 | 2019-03-14 | $50.06 | $1.3M | -14.9% | -16.0% | +0.1% |
| ESPR | SELL | 2018-11-01 | 2018-11-02 | $50.07 | $142K | -17.0% | +3.1% | -16.8% |
| ESPR | SELL | 2018-10-16 | 2018-10-18 | $50.02 | $1.7M | -12.2% | -3.0% | -11.5% |
| ESPR | SELL | 2018-08-27 | 2018-08-29 | $51.05 | $904K | -2.0% | -10.7% | +1.9% |
| ESPR | SELL | 2018-08-17 | 2018-08-22 | $50.06 | $365K | +3.4% | -10.6% | -5.4% |
| ESPR | SELL | 2018-03-29 | 2018-03-29 | $73.26 | $663K | +1.8% | -2.8% | -48.4% |
| ESPR | SELL | 2018-03-29 | 2018-03-29 | $72.37 | $1.8M | +1.8% | -2.8% | -48.4% |
| ESPR | BUY | 2013-07-01 | 2013-07-01 | $14.00 | $593K | -35.3% | -0.8% | -0.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.